BioSpace

NOVEMBER 10, 2021

Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.

Licensing 78

Licensing Licensing Clinical Development Drugs 78

Pharmaceutical Technology

OCTOBER 21, 2022

Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers. On concluding this trial, Roche will gain the right to develop and market the licenced products across various indications, contingent on approval.

Development 278

Development Production Licensing Licensing 278

Outsourcing Pharma

JULY 18, 2023

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

DNA 85

DNA Licensing Licensing Drugs 85

Pharmaceutical Technology

AUGUST 25, 2022

The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial. The company plans to resubmit a Biologics License Application (BLA) for Roctavian by the end of next month.

Gene Therapy 264

Gene Therapy Gene Clinical Trials Clinical Trials 264

Pharmaceutical Technology

OCTOBER 25, 2022

Additionally, Astellas will obtain an exclusive option for licencing two clinical-stage programmes of Taysha, namely TSHA-102 and TSHA-120, for Rett syndrome and GAN, respectively. Astellas will also receive specific rights linked to any possible change of Taysha’s control.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharmaceutical Technology

JUNE 19, 2023

The pharma company will in-license a small number of gene therapy products and offer research grants to advance them through pre-clinical development. Laurus Labs will be responsible for launching these products in India and emerging markets. The company will also establish a GMP facility at IIT Kanpur’s Techno Park facility.

Gene Therapy 246

Gene Therapy Gene Production Pharma Companies 246

Pharmaceutical Technology

JUNE 15, 2023

The deal gives Astellas the option to exclusively license its rights for clinical development and commercialisation for any protein degrader compounds developed within the lead programme. Astellas could pay Cullgen up to $85m upon using its license option regarding the deal.

Protein 130

Protein Development Licensing Licensing 130

pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors.

Licensing 72

Licensing Licensing Trials Clinical Trials 72

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Outsourcing Pharma

JANUARY 13, 2023

A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.

Clinical Development 83

Clinical Development Licensing Licensing Development 83

Pharmaceutical Technology

JANUARY 4, 2023

Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies.

Licensing 130

Licensing Licensing Clinical Development Sales 130

Pharmaceutical Technology

OCTOBER 19, 2022

Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing. Syncromune president and CEO Eamonn Hobbs said: “We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen.

Antibody 130

Antibody Licensing Licensing Containment 130

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Outsourcing Pharma

SEPTEMBER 14, 2023

Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.

Medicine 93

Medicine Licensing Licensing Drugs 93

Pharmaceutical Technology

DECEMBER 6, 2022

Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. According to the agreement, ExpreS 2 ion will hold the exclusive right for licensing the CMV vaccine candidate under a possible development and commercialisation agreement.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Outsourcing Pharma

SEPTEMBER 7, 2022

The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company.

Clinical Development 52

Clinical Development Development Licensing Licensing 52

The Pharma Data

AUGUST 5, 2020

AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Redx is also eligible to receive up to $360m in additional payments, dependent on development, regulatory and commercial milestones, as well as tiered royalties on any future sales.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

Pharmaceutical Technology

AUGUST 11, 2022

They include various patient clinical trials for Disc’s programmes, bitopertin and DISC-0974, which are currently in the clinical development stage. A GlyT1 glycine transporter inhibitor, bitopertin showed effects on heme biosynthesis in clinical trials. Last year, Disc in-licensed bitopertin from Roche.

Medicine 147

Medicine Clinical Trials Clinical Trials Licensing 147

Pharmaceutical Technology

OCTOBER 11, 2022

Swiss biotech company Stalicla has signed a licensing deal with Evgen Pharma for the latter’s lead asset, SFX-01, in neurodevelopmental disorders and schizophrenia. Additionally, Evgen will partner with Stalicla on a clinical programme focused on ASD, with funding for all clinical development activities to come from Stalicla.

Clinical Development 147

Clinical Development Licensing Licensing Clinical Research 147

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. ,

Licensing 52

Licensing Licensing Clinical Development Sales 52

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. Other candidates include a PACAP38 antibody, SSTR4 agonist and TRPA1 antagonist, all in phase 1 development.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

BioSpace

SEPTEMBER 8, 2021

based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans. Durham, N.C.-based

Genome 70

Genome Genomics Licensing Licensing 70

XTalks

FEBRUARY 5, 2025

In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics , a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology.

Clinical Development 59

Clinical Development Development Life Science Clinical Trials 59

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. The company also has several promising agents in early clinical development.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

OCTOBER 18, 2022

Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes. Gilead holds an option for licensing MGD024 as a possible therapy to treat specific blood cancers, including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

Antibody 130

Antibody Development Sales Clinical Trials 130

Outsourcing Pharma

MAY 10, 2024

In an interesting development in the field of rare disease therapeutics, Shionogi & Co., have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease. and Maze Therapeutics, Inc.

Licensing 97

Licensing Licensing Development Clinical Development 97

BioTech 365

SEPTEMBER 18, 2020

Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region Upfront licensing fee of $2.5

Licensing 40

Licensing Licensing Clinical Development Development 40

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

AUGUST 4, 2022

Poseida will carry out the Phase I clinical trials and produce clinical materials for a subset of both the company’s portfolio programmes licensed or optioned to Roche and the companies’ future partnership programmes, before transferring the programmes to the latter for additional development and marketing.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Outsourcing Pharma

MAY 10, 2024

In an interesting development in the field of rare disease therapeutics, Shionogi & Co., have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease. and Maze Therapeutics, Inc.

Licensing 87

Licensing Licensing Development Clinical Development 87

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. .

Development 130

Development Gene Therapy Genetics Gene 130

BioTech 365

APRIL 19, 2021

EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 KAZIA INTENDS TO … Continue reading → DGAP-News: Evotec SE / Key word(s): Miscellaneous 19.04.2021 / 08:31 The issuer is solely responsible for the content of this announcement.

Clinical Development 40

Clinical Development Development Licensing Licensing 40

Worldwide Clinical Trials

FEBRUARY 21, 2024

During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study.

Clinical Trials 200

Clinical Trials Clinical Trials Pharmacy Trials 200

The Pharma Data

JANUARY 5, 2021

COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China. Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged.

Licensing 40

Licensing Licensing Vaccination Vaccine 40

Delveinsight

DECEMBER 8, 2020

KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus. KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market.

Licensing 52

Licensing Licensing Gene Therapy Antibody 52

pharmaphorum

MAY 4, 2022

In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Once selected, Quris can in-license them, progress them through to phase 1 trials and, those that succeed, can be licensed to pharma companies.

Drugs 143

Drugs Licensing Licensing Pharma Companies 143